Aims: To investigate the effect and mechanisms of carbamazepine (CBZ) on the onset and progression of amyotrophic lateral sclerosis (ALS) in SOD1-G93A mouse model. 
| INTRODUC TI ON
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by loss of upper and lower motor neurons (MNs), with an incidence of 2-3 persons per 100 000.
1 About 10% of patients with ALS are inherited due to genetic mutation, while the remaining 90% of cases are sporadic. 2 The median survival of patients is 2-3 years from symptom onset. 1 So far, there are only 2 FDA-approved drugs available for the treatment of ALS, including glutamate antagonist riluzole and antioxidant edaravone. The potential causes for ALS are multifactorial and not fully understood.
Multiple cellular events contribute to the pathobiology of ALS, including oxidative stress, mitochondrial dysfunction, excitotoxicity, protein aggregation, impaired axonal transport, neuroinflammation, and dysregulated RNA signaling.
3
Autophagy is involved in the clearance of long-lived protein aggregation and organelles, 4 and it is a highly conserved and tightly regulated cellular self-degradative process, which degrades long-lived proteins through sequestrating them by double-membrane vesicles called autophagosomes. Then, the autophagosomes are trafficked to fuse with lysosomes or endosomes before merging into lysosomes, which could hydrolysis the sequestrated proteins. of ALS-linked misfolded proteins aggregates, 6, 7 which might activate autophagy. It has been observed that autophagic markers are upregulated in MNs of both ALS patients and animal models. 8, 9 Furthermore, several ALS-causing genes including optineurin (OPTN), sequestosome 1 (SQSTM1), valosin-containing protein (VCP), and dynactin subunit 1 (DCTN1) have been identified to play important roles in autophagy system. 10, 11 Increasing evidence has supported that activation of autophagy might play a protective role in animal models. Lithium has been
shown to influence ALS progression in SOD1-G93A mice through autophagy activation. 12 Trehalose, an enhancer of mammallian target of rapamycin (mTOR)-independent autophagy, could delay ALS onset and reduce MNs loss in SOD1-G93A mice. 13 In contrast, it has been reported that mTOR-dependent activation of autophagy resulted in
MNs loss and survival reducing in SOD1-G93A mice, 14 which may be due to inhibition of mTOR affect other physiological functions of mTOR signaling in neurons including axon guidance, dendritic spine morphogenesis, and dendritic development. 15 Therefore, the mTORindependent activation of autophagy may serve as an ideal strategy for ALS therapy.
Carbamazepine (CBZ) is a well-known anti-epileptic drug used in clinical practice for more than 4 decades. It has been reported that CBZ can stimulate autophagy by decreasing the intracellular level of inositol. 16, 17 We have found that long-term CBZ treatment exhibited a protective effect in a mouse model of Alzheimer's disease possibly through enhancing the autophagic flux. 18 Based on the above-mentioned findings, in this study, we conducted experiments to investigate the potential impacts and mechanisms of CBZ on the onset and progression of ALS in SOD1-G93A mouse model.
| MATERIAL S AND ME THODS

| Transgenic mice and treatment
Transgenic (TG) SOD1-G93A mice overexpressing high-level human mutant SOD1-G93A gene were originally obtained from Jackson Laboratories (B6SJL-Tg-SOD1-G93A-1Gur/J, 002726). 
| Assessment of disease onset and life span
Disease onset was assessed by rotarod test according to our previous study. 21 After 1-week training session, the rotarod test was performed on a 4-cm rod once every other day at a constant speed of 20 rpm for a duration of 5 minutes from 70 days of age until disease onset. If a mouse fell down from the apparatus within 5 minutes, the other 2 tests will be performed after 20-minutes rest. The mice were recorded as a disease onset when the longest run time was less than 5 minutes.
As for the life span, the time of animals death was defined as the day when mice could no longer right themselves when they were placed on their back for 30 seconds. 22 Mice were then sacrificed to reduce further pain from respiratory failure according to animal care guidelines.
| Frozen sections preparation and MNs counting
Three mice in each group were used for the preparation of frozen sections. The mice were anesthetized and perfused with 4% paraformaldehyde (PFA) in phosphate buffer (PBS). The lumbar spinal cord was removed and fixed with 4% PFA overnight at 4°C, followed by dehydrating with 15% and 30% sucrose solution for 24 hour, respectively. Then, the tissues were embedded by optimal cutting temperature (OCT) and cut into serial sections of 10 μm with cryostat microtome. For MNs counting, 1 of every 4 slices and a total of fifty slices were selected for Nissl staining. The MNs in the anterior horns of both sides were counted by an independent investigator who was blinded to genotype and group according to the criterion as described in our previous study. 22 We also counted the number of MNs by immunofluorescent staining with SMI-32
antibody. Twenty slices were collected per animal at an interval of 10 slices. MNs in anterior horns at both sides per slice were counted.
| Pathological analysis of skeletal muscle
The fresh gastrocnemius muscle was dissected and frozen in nhexane at −70°C cooled in liquid nitrogen for 2 minutes. Cross sections (10 μm) were cut using cryostat microtome at −20°C and were stained with hematoxylin and eosin (H&E), nicotinamide adenine dinucleotide hydrogen (NADH), or modified Gomori trichrome (MGT) according to our previously described protocols. The number of NMJ was counted by a researcher blinded to the experimental design.
| Extraction of soluble and insoluble proteins
According to our previously reported protocol, 
| Western blot analysis
After mixing with the loading buffer and boiling at 100°C for 5 minutes, equal amounts of proteins were separated by 8%-12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).
Polyvinylidene 
| Statistical analysis
All data were expressed as the mean ± SEM and analyzed with SPSS 22.0. 
| RE SULTS
| Carbamazepine treatment delayed the disease onset and extended life span of SOD1-G93A mice
Weight loss is a frequent feature of ALS. While WT mice exhibited a gradual increase in body weight, the SOD1-G93A mice showed an inhibited body weight gain. Carbamazepine treatment delayed this body weight loss of TG mice as compared with TG-DMSO group ( Figure 1A ) and reduced mean body weight loss between initial weight and death weight by about 18.1% ( Figure 1B) . Moreover, compared with TG-DMSO group, a significant delay of disease onset was observed in TG-CBZ group as assessed by rotarod test (115.83 ± 1.37 days vs 101.17 ± 1.20 days, P < .001; Figure 1C ).
Carbamazepine treatment delayed the disease onset by about 14.5%
( Figure 1D ). Carbamazepine treatment also significantly extended the life span of SOD1-G93A mice by about 13.9% (153.75 ± 2.76 days vs 134.9 ± 3.46 days, P < .001; Figure 1E ,F). There was no significant difference in disease duration among 2 groups (37.92 ± 2.64 days vs 33.50 ± 2.22 days, P = .215).
| Carbamazepine treatment alleviated the MNs loss in the anterior horn of SOD1-G93A mice
The Figure 3A) . The average muscular fiber area in TG-CBZ group was significantly larger than that in TG-DMSO group (1238.1 ± 53.8 μm 2 vs 748.6 ± 37.8 μm 2 , P < .001; Figure 3B ). modified Gomori trichrome staining also showed a decreased muscle atrophy in TG mice treated with CBZ ( Figure 3C ), indicating a protective effect of CBZ on muscular fiber. Then, we assessed the metabolic muscle phenotype by determining the proportion type I fibers using NADH staining. Our data revealed that the type I fibers (dark blue) in TG mice were significantly increased. There was lower ratio of type I fiber in TG-CBZ group than that in TG-DMSO group, although difference did not reach statistical significance ( Figure 3D ,E).
These data suggested that CBZ treatment had a protective role on muscle morphology in SOD1-G93A mice.
Neuromuscular junction destruction is an early pathological change in SOD1-G93A mice. 23 We labeled NMJs on cross section of gastrocnemius muscle using α-bungarotoxin. While SOD1-G93A mice showed a significant NMJs degeneration compared with WT littermates, the number of NMJs in TG-CBZ group was better preserved than that in TG-DMSO group (9.06 ± 0.49 vs 6.17 ± 0.35, P = .005; Figure 3F ,G).
| Carbamazepine treatment reduced mutant SOD1 protein aggregation which was associated with autophagy activation
Mutant SOD1 aggregates are involved in the pathogenesis of ALS, 24 and reducing mutant SOD1 protein aggregation is regarded as an effective strategy to treat ALS. 25 Carbamazepine have been reported to promote the degradation of mutant α1-antitrypsin Z protein, 
| Carbamazepine treatment activated autophagy through AMPK-ULK1 (Ser555) pathway
Inhibition of mTOR signaling is an important initiator of autophagy.
Here, we investigated the potential involvement of mTOR pathway 
| D ISCUSS I ON
A large number of promising drugs have been preclinically discovered and showed successful therapeutic effects in various ALS animal models, but most of them failed to demonstrate clinical efficacy.
Single-factor or single-target treatments such as antioxidants alone seem unlikely to stop ALS progression due to the multifactorial nature of ALS. 26 Multifactorial combination therapy or multitargets therapy may be a choice for ALS treatment such as riluzole, which not only modulates glutamatergic transmission, but also modulates sodium channel current and inhibits neurotransmitter release. 27 As an old drug for the treatment of epilepsy, CBZ also shows neuroprotective effects through a variety of mechanisms including inhibition of glutamate release, antagonizing glutamate receptor and modulating signal transduction. 28 We revealed that CBZ treatment could not only delay the disease onset and extend life span of SOD1-G93A
mice, but also alleviate the MNs loss and morphological damage of muscle and protect neuromuscular junction. Moreover, many failed studies only focused on survival impact but lack the result of potential impact on quality of life. These findings indicated that CBZ may Misfolded protein aggregation is a major pathological feature of ALS, which is detected in spinal cord even at the presymptomatic stage, and may propagate via cell-to-cell transmission. 29, 30 Accumulation of mutant SOD1 aggregates has been proposed to result in MNs loss by gain of function toxicity and inhibition of a multitude of cellular function including axonal transport, mitochondrial function, and protein homeostasis. 31 Clearance of mutant SOD1
aggregates played a protective role in reducing MNs damage. 13, 32, 33 We found CBZ treatment reduced monomeric and aggregated mutant SOD1 proteins in lumbar spinal cord, which might contribute to CBZ-induced neuroprotection in ALS mice. Consistent with our findings, CBZ treatment has been reported to promote the clearance of abnormal protein aggregation in several other diseases, such as hepatic fibrosis and fibrinogen storage disease. 16, 34 Autophagy is a main pathway for degradation of SOD1 aggregates. Moreover, a dysregulated autophagy has been observed in ALS. 10 Increased expression levels of LC3-II and p62 have been found in spinal cord of SOD1-G93A mice, and electron microscopy observation has also revealed accumulations of autophagic vacuoles in this TG animal model of ALS.
14 In our present study, CBZ treatment could reduce p62 accumulation and increase expression of Beclin1.
P62 could bind ubiquitylated protein aggregates and deliver them to the autophagosomes. Meanwhile, p62 is also constantly degraded via nonselective autophagy through its LIR domain that binds to LC3 on autophagosome membranes. and AMPK, which is essential for autophagosome biogenesis. In addition to regulating autophagy, mTOR pathway also promotes lipid biosynthesis and regulates glucose metabolism and mitochondrial function. Inhibition of mTOR pathway may have negative impacts on age-related diseases. 40 We found CBZ treatment did not affect the expression of the key proteins in mTOR pathway including p-mTOR, p-AKT, and p-P70S6K, especially the phosphorylation level of ULK1 at Ser757 site, suggesting mTOR-independent mechanisms might be involved in CBZ-induced autophagy.
AMPK could directly activate autophagy by phosphorylating ULK1 at multiple sites including Ser555. Loss of AMPK or ULK1
resulted in aberrant accumulation of the autophagy adaptor p62
In mammals. 41 In ALS mice, the phosphorylation levels of AMPK were reduced in spinal cord at the end stages of the disease. . The values were presented as mean ± SEM, *P < .0125, **P < .001, Scale bar = 10 μm extend survival in ALS mice. 43, 44 Consistent with our present data, previous studies have also reported that CBZ treatment could induce AMPK activation and promote ULK1 phosphorylation at Ser555 site through inositol-1,4,5-triphosphate (IP3) depletion. 16, 17 Carbamazepine also prevent calcium overloading in mitochondria and increase expression of Beclin1 and ATG7 by suppressing calpain activation.
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Of course, neuronal hyperexcitability was also an important feature of ALS. It has been reported that the faster firing cluster MNs appeared hyperpolarization at 2-3 months of age and lost at 4 months of age in SOD1-G85R mice. F I G U R E 6 Carbamazepine activated autophagy by AMPK-ULK1 pathway. Western blots and quantitative analysis for P-AKT/AKT (A,B), P-mTOR/mTOR (C,D), P-P70S6K/P70S6K (E, F), P-ULK1 (ser757) (G,H), AMPK (I,J), P-AMPK (K,L), and P-ULK1 (ser555) (M,N) protein level in each group. n = 3 in each group. The values were presented as mean ± SEM, *P < .0125
